Suven Life Sciences Limited Share Price and Company Fundamentals
Last traded: Today at 7:32 AM
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Key Metrics
PE ratio
-
PB ratio
17.07
Dividend yield
-
Beta
0.80
Market cap
₹108.15B
Enterprise value
₹93.31B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 142 |
| Website | https://www.suven.com |
| Mailing address | 8-2-334, SDE Serene Chambers 6th Floor Road No.5, Avenue 7 Banjara Hills, Telangana Hyderabad 500034 India |
| Phone / Fax | 91 40 2354 1142 / 91 40 2354 1152 |
Dividends
Dividend yield
-
Dividend amount
₹-
Payout ratio
0.00%
5Y Avg. yield
-%
Suven Life Sciences Limited paid ₹- dividend and the ex-dividend date was 14 Feb 2019.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.SUVEN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Sep 2026, following are the company executives and directors listed on Suven Life Sciences Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Venkateswarlu Jasti M.Pharm. M.S. | CEO, MD & Executive Chairman | 76 | |
| Dr. N. V. S. Ramakrishna M.Sc, Ph.D. | President & Chief Scientific Officer | 63 | |
| Ms. Sudharani Jasti B.Sc. | Whole-Time Director | 71 | |
| Mr. M. Mohan Kumar C.M.A. | Chief Financial Officer | ||
| Ms. Sangeetha Laxmi Kandari | Company Secretary & Compliance Officer | ||
| Ms. Kalyani Jasti | President of US Operations | 46 |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-3776.37%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Suven Life Sciences Limited is 108.15B and its enterprise value is 93.31B. The enterprise value to revenue ratio of SUVEN is 1058.73. The enterprise value to EBITDA ratio of SUVEN is -25.42.
The SUVEN's stocks Beta value is 0.80 making it 20% less volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Suven Life Sciences Limited (NSE:SUVEN) Frequently Asked Questions
1. What is Suven Life Sciences Limited's Stock Symbol?
Suven Life Sciences Limited trades on NSE under the ticker symbol "SUVEN".
2. What is Suven Life Sciences Limited's stock price today?
One share of SUVEN stock can currently be purchased for approximately ₹382.75.
3. How can I contact Suven Life Sciences Limited?
Suven Life Sciences Limited's mailing address is 8-2-334, SDE Serene Chambers 6th Floor Road No.5, Avenue 7 Banjara Hills, Telangana Hyderabad 500034 India. The company can be reached via phone at 91 40 2354 1142.
4. What is Suven Life Sciences Limited's official website?
The official website of Suven Life Sciences Limited is https://www.suven.com.